Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by toinv261on Dec 31, 2021 1:40pm
208 Views
Post# 34274423

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Screening

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ScreeningRight on geric. Don has accomplished nothing since the end of BoM yet he has rewarded himself handsomely.

What is difficult to understand is why seemingly good scientists like Doctor Wong would want to remain associated with a snake oil salesman like Don. Dr Wong owns a couple of million shares, from what I recall, so why does he let a snake like Don erode the value of his science? Strange. Is it just  that the sugar daddy keeps enough money flowing to continue the science?

What is RVX afraid of? They seem to have the science to attract the biggest and best brains in science and financing. Yet they leave a loser like Don as COB/CEO/President of this break through science biotech???? (and ZCC). This is an uneducated man in charge of and in complete control of a potentially breakthrough, multibillion dollar biotech and he has accomplished nothing.

It is almost unimagineable that someone could be that incompetent and yet be the boss of brilliant scientists that probably have created an entirely new approach to managing CVD and CKD.

Or am I wrong on the science assumption?? We've seen promising publications in journals but they do not seem to have value.

So sit back and think deeply on this last day of the year about this and if it makes any sense at all to be traded at $0.51 CDN? This is the definition of incompetence!

The best New Years gift will be for Don to resign and better yet to have a new CEO with biotech experience and a background in finance and independent from ORI Capital and Hepa. Someone honest at least!

Hopefully Don's grotesque compensation this year was nothing but a "good bye" reward.

Happy New Year.
Toinv      :)

<< Previous
Bullboard Posts
Next >>